# A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

> **NCT03093025** · PHASE2 · TERMINATED · sponsor: **Taisho Pharmaceutical R&D Inc.** · enrollment: 51 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** TS-121 10 mg
- **DRUG:** TS-121 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03093025
- **Lead sponsor:** Taisho Pharmaceutical R&D Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-03
- **Primary completion:** 2018-11-08
- **Final completion:** 2018-12-04
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2020-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093025, "A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03093025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*